Skip to main content
All Posts By

cece

ResearchTreatments

Oleclumab Plus Osimertinib Show Early Activity and Tolerability EGFR-Mutant NSCLC

*May 2021* Note: Is further evaluation of the combination warranted for patients with locally advanced or metastatic T790M-negative, EGFR-positive NSCLC? The combination of oleclumab (MEDI9447) and osimertinib (Tagrisso) was well-tolerated and demonstrated preliminary anti-tumor activity in patients with non-small-cell lung cancer (NSCLC) with an epidermal growth factor receptor mutation (EFGR) mutation…
cece
September 7, 2021
ResearchTreatments

Osimertinib Combinations as Second-Line Treatment in Non-Small Cell Lung Cancer: The Jury’s Still Out

*July 2021* Note  Should a VEGF inhibitor (bevacizumab/Avastin) be combined with osimertinib or not? The role of osimertinib combinations as second-line treatment for advanced non-small cell lung cancer (NSCLC) is still unclear, according to researchers. Osimertinib is a standard first-line treatment option for patients with advanced NSCLC and EGFR mutations, but progression on this…
cece
September 7, 2021
ResearchTreatments

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response

*ASCO 2021* Background: Preliminary efficacy was observed with the combination of amivantamab, an EGFR-MET bispecific antibody, and lazertinib, a 3rd-generation tyrosine kinase inhibitor, in both treatment-naïve and osimertinib (osi)-relapsed patients (pts) with EGFRm NSCLC (Cho Ann Oncol 2020;31:S813). We present updated results of the combination in osi-relapsed pts, including an…
cece
September 6, 2021
ResearchTreatments

Clinical Challenge: Optimal Therapies for Rare EGFR Mutations in NSCLC

*June 2021* — Patients harboring these uncommon mutations may need "special selection of EGFR TKIs" EGFR mutations in non-small cell lung cancer (NSCLC) were first pinpointed in 2004. These mighty mutations have emerged as the strongest predictor of response to EGFR tyrosine kinase inhibitor (TKI) therapies, with deletions in exon 19 and the point…
cece
September 6, 2021
Coping With Cancer

Talking to Your Children About Cancer

*July 2021*  Written by Tess Taft, MSW, LICSW, and oncology psychotherapist.© “I feel like I’m doing something terrible to my family even though I didn’t ask for this.” “My friends and family don’t get it. They can’t. I finally let them off the hook.” “My teenager wants to know ALL…
cece
September 6, 2021
ResearchTreatments

Aumolertinib vs Gefitinib for NSCLC EGFR exon 19 del or L858R mutations

*ASCO 2021* Note: Could this become a less-expensive alternative to osimertinib? Background: Au is a novel, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) with favorable pharmacologic properties that selectively inhibits both EGFR sensitizing and resistance mutations. Au has been approved in China for treatment of patients (pts)…
cece
September 6, 2021
ResearchTreatments

Patritumab deruxtecan shows promise for EGFR inhibitor-resistant NSCLC

*April 2021* Note: This trial indicates that this might be a good treatment for post-Tagrisso progression, even in heavily pre-treated patients. Dr. Pasi Jänne shares updated phase 1 data on the antibody–drug conjugate patritumab deruxtecan in advanced EGFR-mutated non-small-cell lung cancer patients who have developed resistance to EGFR inhibitors. Watch…
cece
September 6, 2021
ResearchTreatments

Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report

*April 2021* Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated NSCLC and LM disease progression through osimertinib 80 mg daily, with subsequent durable radiographic and symptomatic response to systemic pemetrexed in combination with osimertinib. This builds on the limited data evaluating…
cece
June 24, 2021